Pfizer unleashes wave of breakthrough cancer data at ASCO 2026
Pharma giant targets new standards of care
Pharma giant targets new standards of care
The drug also showed a manageable safety profile, with just 6.4% of patients stopping treatment due to side effects. No new safety concerns emerged
Subscribe To Our Newsletter & Stay Updated